Electrochemical-based method achieves rapid AST results in urine samples, supporting antimicrobial stewardship and indicating high concordance with standard tests.
Antimicrobial resistance (AMR) poses a major global health threat, often driven by empirical antibiotic use due to the relatively slow (24-72 hour) diagnostic pathway for urinary tract infections (UTIs). Due to their low cost and ease of multiplexing, electro-chemical biosensors offer a promising alternative. Herein, we report on the Microplate Dx RapidPlate™ platform, a rapid electrochemical impedance spectroscopy (EIS) based approach for accelerated antibiotic susceptibility testing (AST) directly from urine samples, without pre-treatment. This report charts the evolution of the core EIS based AST measurement from laboratory proto-type into fully realised Alpha prototype platform with an accompanying 32-channel electrochemical cartridge designed specifically for interrogation of urine samples. A total of 89 clinically derived urine samples were evaluated at three clinical sites (UK and India), with results compared against standard methods (VITEK 2 and disk diffusion). The impedance based RapidPlate™ system detected bacterial growth within 50 minutes and provided susceptibility profiles by 85 minutes, with 94% concordance to reference tests. Consistent performance is demonstrated across diverse clinical settings and organisms, including Escherichia coli and Klebsiella pneumoniae. The RapidPlate™ AST system has demonstrated great potential as a cost-effective, point-of-care tool for rapid AST, supporting and improving UTI management and antimicrobial stewardship.
No takes yet. Share an insight, caveat, or question.
Ralston et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: